1.81

1.81 (-0.79%)

As of Jun 14, 2022

Galecto, Inc. [GLTO]

Source: 

Company Overview

We are a clinical-stage biotechnology company developing therapeutics that are designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Our initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2, which play key roles in regulating fibrosis and cancer. We believe our product candidates are distinct from the current generation of antifibrotic and anticancer agents and have the potential to significantly improve patients clinical outcomes and enhance their quality of life.

CountryUS
Headquartersbostonmassachusetts
Phone Number(457) 070-5210
Industrypharmaceutical preparations
CEOHans T. Schambye, M.D., Ph.D.
Websiteclinicaltrials.gov

Recent Stories